Hahn RG, Temkin NR, Savlov ED, Perlia C, Wampler GL, Horton J, Marsh J, Carbone PP. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer.
CANCER TREATMENT REPORTS 1978;
62:1093-5. [PMID:
356971]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
One hundred and sixty-five patients with advanced renal cell cancer were evaluable for combination or single-agent therapy with methyl-CCNU, vinblastine, and medroxyprogesterone. A low order or response was observed, and these agents were not proven effective as treatment for metastatic renal cell cancer. Performance status and a relatively long symptom-free interval from primary tumor to metastatic disease were found to be the most prognostically significant factors for survival.
Collapse